

Special Issue

Leveraging Immune Checkpoint Blockades-Based Combined Therapy to Overcome Adaptive Immune Resistance

Message from the Guest Editor

Tumors employ various tactics to adapt to and eventually resist immune attack, collectively called adaptive immune resistance (AIR). Despite the recent success of immune checkpoint blockades (ICBs) that were found to induce systemic regression of tumors and prolong survival, AIR has held the field back from wider success. As ICBs can treat subsets of ‘inflamed’ cancers infiltrated by pre-primed tumor-reactive T cells, several novel approaches (such as CAR-T, oncolytic virus, and cancer vaccines) have the potential to newly prime tumor-reactive T cells. Therefore, combining ICBs with novel immunotherapy would lead to enhanced treatment of a larger fraction of human cancers in the near future. Based on your expertise in cancer immunotherapy, you are invited to contribute a research paper or review in this Special Issue to highlight the remaining challenges for translation medicine to achieve a selective and durable anti-tumor immune response in advanced cancer patients. Studies focusing on ICBs and adaptive immune resistance through both clinical and pre-clinical investigations are welcome.

Guest Editor

Dr. Chunchao Zhu

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200232, China

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/151315

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).